Ceretas Limited Initiates $8 Million Share Offer at $0.25 Per Share Ahead of ASX Debut

Ceretas' Strategic $8 Million Capital Raise to Drive Product Development and Market Entry

Ceretas Limited is conducting a public capital raise of $8 million before costs to support operations and advance its licensed product portfolio. The company plans to issue 32 million ordinary shares at $0.25 each through a combination of public and secondary offers detailed in the prospectus. This capital raise reflects Ceretas’ intention to establish a public equity base as it progresses toward ASX listing and commercial milestones. The share pricing and volume represent the company's valuation as it transitions from private to publicly listed status.

The current prospectus is a replacement, following the original lodged on 12 June 2026 and a first replacement on 19 June 2026, reflecting ongoing refinements to deal terms and disclosures as Ceretas finalised arrangements with commercial partners and ASX documentation. Joint lead managers Caravel Securities Pty Ltd and Taurus Capital Group Pty Ltd are overseeing the public offer, signaling institutional support for the capital raise.

Revised UniQuest Licensing Agreement with Adjusted Payment Terms

The replacement prospectus reveals significant amendments to Ceretas’ intellectual property licensing agreement with UniQuest. Notably, the company has removed cash milestone payments originally due upon submission of licensed products to regulatory bodies such as the Therapeutic Goods Administration (TGA), the European Union, or the United States. This change reduces projected cash outflows linked to regulatory milestones and suggests renegotiation of licensing terms or reassessment of regulatory pathways.

In addition to milestone payment removal, Ceretas has restructured annual fee payments payable to UniQuest after the first commercial sale of a licensed product. Although specific details are not disclosed, the prospectus notes these fees have been varied. Furthermore, Ceretas increased consideration shares payable to UniQuest by 400,000 shares, adjusting the total shareholding upon assignment triggers. These licensing modifications are not materially adverse from an investor perspective compared to prior prospectuses, and no withdrawal rights have been granted to existing applicants.

ASX Listing Application and Timeline for Market Entry

Ceretas has formally applied for ASX official quotation of its shares, marking a key step in its transition to a publicly listed company. Lodgement of the prospectus with ASIC on 7 July 2026 sets the regulatory framework for public market entry. ASIC and ASX disclaim responsibility for the prospectus content or investment merits, consistent with regulatory norms. The prospectus expires 13 months from the original date, defining the timeframe for application processing and capital raise completion.

Listing on the ASX will require Ceretas to comply with continuous disclosure obligations, shareholder reporting, and regulatory standards for listed entities. The prospectus underscores that no information beyond its contents is authorized for investment decisions, and investors should rely solely on the prospectus. The company, its share registry Automic Pty Ltd, and joint lead managers disclaim liability for trading before holding statements are issued.

Biomedical Sector Focus and Licensed Product Pipeline

Ceretas operates within the biomedical industry, focusing on commercialising licensed products. References to regulatory submissions to the TGA and equivalent authorities in Europe and the US indicate the company is advancing therapeutics or medical products requiring formal approval in major markets. The milestone payment restructuring suggests progress toward regulatory submission phases and a multi-jurisdictional approval strategy aimed at global commercialisation.

UniQuest’s role as an IP licensor highlights Ceretas’ reliance on technology transfer from academic research, as UniQuest is affiliated with the University of Queensland. The licensing agreement adjustments, including increased consideration shares and payment term revisions, reflect ongoing commercial evolution as Ceretas advances its product pipeline toward commercialisation. The business model depends on progressing licensed technologies through development, regulatory approval, and first commercial sales, which trigger annual fee payments.

Investment Risks and Considerations for Potential Investors

The prospectus categorizes investment in Ceretas as "highly speculative," directing investors to Section 5 for a detailed risk summary. The company emphasizes its securities carry high risk and require investors to have suitable risk tolerance and investment horizons. The information is not financial advice and does not consider individual circumstances; investors are urged to consult professional advisers before investing.

Risks typical of biomedical development companies apply, including uncertain regulatory approval timelines and costs. Dependence on UniQuest for IP creates counterparty risk. Commercial success hinges on regulatory approval, manufacturing, market acceptance, and competitive factors. The milestone payment adjustments indicate reassessment of cost structures and timelines, though reasons are not detailed.

Corporate Governance and Disclosure Compliance

Ceretas is an Australian proprietary company limited by shares (ACN 681 662 224). The prospectus serves as the formal disclosure document for the capital raise, demonstrating commitment to regulatory compliance and transparent governance. It includes a target market determination (TMD) under the Corporations Act design and distribution obligations, available at https://ceretas.com.au/. Applicants warrant they have read and fall within the target market.

The three prospectus versions reflect iterative regulatory engagement and deal refinements. Directors state the current replacement prospectus is not materially adverse compared to earlier versions, indicating no fundamental change to the investment proposition for existing applicants.

Joint Lead Managers and Capital Raise Structure

Caravel Securities Pty Ltd (ACN 665 357 915) and Taurus Capital Group Pty Ltd (ACN 622 499 834) serve as joint lead managers for the public offer. Neither entity authorized the prospectus issuance and disclaim liability beyond name references. Their joint management covers distribution, marketing, and settlement of the offer. Neither makes warranties regarding prospectus accuracy.

The offer comprises a primary public share offer at $0.25 per share, secondary offers (detailed in Section 7.2), and joint lead manager options. This multi-tranche structure accommodates retail and institutional investors, recognizes prior investors or service providers, and compensates advisors via equity. The choice of regulated joint lead managers indicates institutional confidence in the capital raise and listing prospects.

Regulatory Timeline and Prospectus Validity

The prospectus sets a 13-month expiry from the original 12 June 2026 date, defining the period for application processing and capital raising. A mandatory seven-day exposure period after the original lodgement prevents application processing, allowing regulator and market review. No securities will be issued post-expiry, establishing a capital raise deadline.

Disclaimers clarify no warranties or guarantees exist regarding company performance or investment returns. The company, share registry, and joint lead managers disclaim liability for trading before holding statements are issued, reflecting standard market practice distinguishing prospectus liability from trading liability. The prospectus is the exclusive source for investment decisions.

Prospectus Revisions Reflect Ongoing Commercial Negotiations

The progression from the original 12 June 2026 prospectus through two replacements reflects dynamic pre-listing development. The first replacement on 19 June 2026 introduced UniQuest licensing amendments, with the second replacement on 7 July 2026 further refining these changes. Key revisions include removing cash milestone payments tied to regulatory submissions and restructuring annual fees post-first commercial sales, indicating active licensing negotiations.

The additional 400,000 consideration shares granted to UniQuest in lieu of cash milestones suggests Ceretas prioritizes cash preservation for operations and development during pre-commercialisation. The prospectus confirms these amendments are not materially adverse to investors, providing reassurance despite multiple prospectus versions. Prospective investors should carefully review all versions to fully understand commercial obligations and capital structure.